ClinicalTrials.gg
RecruitingNCT04414475Updated Oct 29, 2026

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

A Phase 2 interventional study of Selinexor and Dexamethasone in Multiple Myeloma, Refractory, sponsored by Karyopharm Therapeutics Inc. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.
Updated Oct 29, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing selinexor in Multiple Myeloma — 12 open to participants now, 21 under way, 3 of them phase 3. selinexor · Multiple Myeloma.

Planned enrollment
6th of 38
127 · median 45
Started
2020
with 1 other
Phase 2
19 of 38
6 open now
Primary completion
2028-01
later than 17 of 20 live
Registered
14th of 38
by date
Lead sponsor
6 of 38
Karyopharm Therapeutics Inc

Among the 38 studies testing selinexor in Multiple Myeloma, this one is the 6th largest by planned enrollment, is one of 2 that started in 2020, is one of 19 in phase 2, reaches primary completion later than 17 of the 20 other live ones, and was the 14th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 38 studies testing selinexor in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing selinexor in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma, Refractory

Browse trials for

Keywords

  • Multiple Myeloma
  • Selinexor
  • Penta-refractory Multiple Myeloma
  • Triple-class Refractory Multiple Myeloma
  • KPT-330
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to (>=)18 years at the time of signing .
  • Written informed consent in accordance with federal, local, and institutional guidelines.
  • Measurable MM based on IMWG guidelines as defined by at least one of the following:

    1. Serum M-protein >= 0.5 gram per deciliter (g/dL) by serum protein electrophoresis (SPEP) or, for Immunoglobulin (Ig) A myeloma, by quantitative IgA.
    2. Urinary M-protein excretion >= 200 mg/24 hours.
    3. Free light chain (FLC) >= 100 milligram per liter (mg/L), provided that the FLC ratio is abnormal.
  • Only for arms Sd-40 BIW, Sd-100 QW and Sd-80 BIW prior to protocol version (PV) 5.0: Participants must have multiple myeloma (RRMM) and have previously received at least 4 anti-MM prior therapies and have MM that is refractory to previous treatment with at least 2 proteasome inhibitors (PIs), at least 2 immunomodulatory agent (IMiDs), and 1 anti-cluster of differentiation (CD38) monoclonal antibody. Refractory is defined as lesser than or equal to (\<=) 25 percent (%) response to therapy, or progression during therapy or progression within 60 days after completion of therapy.
  • Only for Arms Sd-40 BIW and Sd-100 QW as of PV 5.0: Participants must have RR MM and have been previously treated with >=3 anti-MM therapies (with exposure to at least 2 PI drugs, at least 2 IMiDs, and 1 anti-CD38 monoclonal antibody), and be refractory to at least 1 drug of each class (PI/IMiD/anti-CD38). Refractory is defined as \<=25% response to therapy or progression during therapy or progression within 60 days after completion of therapy.
  • Only for arm SVd: Participants must have previously received 1 to 5 anti-MM prior therapies and have MM that is refractory to previous treatment with at least 1 PI, at least 1 IMiD, and 1 anti- CD38 monoclonal antibody.
  • (ECOG) performance status of \<= 2.
  • Female participants of must agree to use dual methods of and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female participants, effective methods of contraception must be used throughout the study and for 7 months for female and 4 months for male following the discontinuation of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Active plasma cell leukemia.
  • Documented systemic amyloid light chain amyloidosis.
  • Active central nervous system MM.
  • Only for SVd arm: Greater than Grade 2 peripheral neuropathy or Grade >= 2 peripheral neuropathy with pain at baseline, regardless of whether or not the participant is currently receiving medication.
  • Radiation, chemotherapy, immunotherapy, or any other anticancer therapy (including therapies) \<= 2 weeks prior to Cycle 1 Day 1 (C1D1). ( are permitted up to 1 pulse of 40 mg per day for 4 days in the 2 weeks prior to C1D1).
  • Active graft vs. host disease (after stem cell transplantation) at C1D1.
  • Ongoing non-hematological toxicities from prior treatments that are Grade greater than (>) 2 at C1D1.
  • Inadequate hepatic function defined as total >= 2x (ULN) (>= 3x ULN for participants with Gilbert's syndrome), (AST) >= 2.5x ULN, and alanine transaminase (ALT) >= 2.5x ULN.
  • Inadequate renal function defined as estimated of lesser than (\<) 20 milliliter per minute (mL/min), calculated using the formula of Cockroft and Gault.
  • Inadequate hematopoietic function defined as the following:

    1. (ANC) \< 1000/cubic millimeter (mm\^3)
    2. count \< 75,000/mm\^3
    3. (Hb) level \< 8.5 g/dL
  • of \< 4 months, based on the opinion of the Investigator.
  • Major surgery within 4 weeks prior to C1D1.
  • Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose.
  • Active gastrointestinal dysfunction interfering with the ability to swallow tablets, or any gastrointestinal dysfunction that could interfere with absorption of the study treatment.
  • Known active hepatitis A, B, or C infection; or known to be positive for virus RNA or virus surface antigen.
  • Female participants who are pregnant or lactating.
  • Known intolerance, , or to glucocorticoid therapy at C1D1.
  • Concurrent therapy with approved or investigational anticancer therapeutic including topical therapies.
  • Prior exposure to a SINE compound, including selinexor.
  • Serious, active psychiatric or active medical conditions which, in the opinion of the Investigator or the Sponsor, could interfere with the participation in the study.
  • Contraindication to any of the required concomitant drugs or supportive treatments.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (estimated)

Study arms

  • Experimental
    Selinexor + Low-dose Dexamethasone (Sd-40 BIW)

    Participants will receive fixed dose of 40 milligram (mg) of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet twice weekly (BIW) on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle.

    Drug: Selinexor · Drug: Dexamethasone

  • Experimental
    Selinexor + Low-dose Dexamethasone (Sd-100 QW)

    Participants will receive fixed dose of 100 mg of Selinexor oral tablet followed by 40 mg of low-dose Dexamethasone oral tablet once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone may be given as 20 mg on days 1 and 2 of each week at the discretion of the treating physician).

    Drug: Selinexor · Drug: Dexamethasone

  • Experimental
    Selinexor + Low-dose Dexamethasone (Sd-80 BIW)

    Participants will receive fixed dose of 80 mg of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet BIW on Days 1, 3, 8, 10,15, 17, 22, and 24 of each 28-day cycle. Closed for recruitment.

    Drug: Selinexor · Drug: Dexamethasone

  • Experimental
    Selinexor + Bortezomib + Dexamethasone (SVd)

    Participants will receive fixed dose of 100 mg of Selinexor oral tablet on Days 1, 8, 15, 22, and 29 followed by 1.3 milligram per square-meter (mg/m\^2) of Bortezomib subcutaneous (SC) injection on Days 1, 8, 15, and 22 and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, 22, and 29 of each 35-day cycle (Dexamethasone dose may be split to 20 mg on days 1 and 2 of each week at the discretion of the treating physician). Closed for recruitment.

    Drug: Selinexor · Drug: Dexamethasone · Drug: Bortezomib

Interventions

  • Participants will receive Selinexor oral tablets.

    Also known as: KPT-330, XPOVIO

  • Participants will receive Dexamethasone oral tablets.

    Also known as: Decadron

  • Participants will receive Bortezomib SC injection.

    Also known as: Velcade

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: From the date of randomization up to death (approximately 60 months)

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: From the date of randomization to first disease progression or death (approximately 60 months)

  2. Clinical Benefit Rate (CBR)

    Time frame: From the date of randomization up to death (approximately 60 months)

  3. Disease control rate (DCR)

    Time frame: From the date of randomization up to death (approximately 60 months)

  4. Progression-Free Survival (PFS)

    Time frame: From the date of randomization to first disease progression or death (approximately 60 months)

  5. Overall Survival (OS)

    Time frame: From the date of randomization up to death (approximately 60 months)

  6. Time to Next Treatment (TTNT)

    Time frame: From the date of first dose up to death (approximately 60 months)

  7. Number of Participants with Adverse Events (AE)

    Time frame: From start of study drug administration up to follow-up (approximately 60 months)

07

Study locations

6 of 16 sites recruiting
08

References and documents

Publications

  • White D, Schiller GJ, Madan S, Lentzsch S, Chubar E, Lavi N, Van Domelen DR, Bentur OS, Baljevic M. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Front Oncol. 2024 May 17;14:1352281. doi: 10.3389/fonc.2024.1352281. eCollection 2024. PubMed 38826786 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jan 2028, 90 months after the start.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 90 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 4, 2020
StartActual
Jul 1, 2020
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites changed recruiting status (5 now completed, 3 now active, not recruiting)
Show 8 sites
  • Emek Medical Center · Afula, IsraelRecruiting→Active, not recruiting
  • Bnai-Zion Medical Center · Haifa, IsraelRecruiting→Completed
  • Shaare Zedek Medical Center · Jerusalem, IsraelRecruiting→Active, not recruiting
  • Rabin Medical Center (Beilinson Hospital) · Petah Tikva, IsraelRecruiting→Completed
  • The Chaim Sheba Medical Center at Tel HaShomer · Ramat Gan, IsraelRecruiting→Completed
  • Tel Aviv Sourasky Medical Center · Tel Aviv, IsraelRecruiting→Completed
  • Soroka University Medical Center · Beersheba, IsraelActive, not recruiting→Completed
  • Assuta Ashdod Medical Center · Ashdod, IsraelRecruiting→Active, not recruiting
across 2 updates, Oct 1, 2026 – Oct 29, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • Emek Medical Center · Afula, IsraelContact removed C•••@clalit.org.il · •••8012Contact removed (no phone or email listed)
  • Bnai-Zion Medical Center · Haifa, IsraelContact removed T•••@b-zion.org.il · •••8114Contact removed (no phone or email listed)
  • Shaare Zedek Medical Center · Jerusalem, IsraelContact removed g•••@szmc.org.il · •••2046Contact removed (no phone or email listed)
  • Rabin Medical Center (Beilinson Hospital) · Petah Tikva, IsraelContact removed a•••@clalit.org.il · •••1033Contact removed (no phone or email listed)
  • The Chaim Sheba Medical Center at Tel HaShomer · Ramat Gan, IsraelContact removed h•••@sheba.health.gov.il · •••5432Contact removed (no phone or email listed)
  • Tel Aviv Sourasky Medical Center · Tel Aviv, IsraelContact removed y•••@tlvmc.gov.il · •••2575Contact removed (no phone or email listed)
  • Assuta Ashdod Medical Center · Ashdod, IsraelContact removed m•••@assuta.co.il · •••9161Contact removed (no phone or email listed)
across 2 updates, Oct 1, 2026 – Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    Assuta Ashdod Medical Center is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Assuta Ashdod Medical Center · Ashdod, IsraelContact removed m•••@assuta.co.il · •••9161Contact removed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 1, 2026
    7 sites changed recruiting status (5 now completed, 2 now active, not recruiting)
    Show 7 sites
    • Emek Medical Center · Afula, IsraelRecruiting→Active, not recruiting
    • Bnai-Zion Medical Center · Haifa, IsraelRecruiting→Completed
    • Shaare Zedek Medical Center · Jerusalem, IsraelRecruiting→Active, not recruiting
    • Rabin Medical Center (Beilinson Hospital) · Petah Tikva, IsraelRecruiting→Completed
    • The Chaim Sheba Medical Center at Tel HaShomer · Ramat Gan, IsraelRecruiting→Completed
    • Tel Aviv Sourasky Medical Center · Tel Aviv, IsraelRecruiting→Completed
    • Soroka University Medical Center · Beersheba, IsraelActive, not recruiting→Completed
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Emek Medical Center · Afula, IsraelContact removed C•••@clalit.org.il · •••8012Contact removed (no phone or email listed)
    • Bnai-Zion Medical Center · Haifa, IsraelContact removed T•••@b-zion.org.il · •••8114Contact removed (no phone or email listed)
    • Shaare Zedek Medical Center · Jerusalem, IsraelContact removed g•••@szmc.org.il · •••2046Contact removed (no phone or email listed)
    • Rabin Medical Center (Beilinson Hospital) · Petah Tikva, IsraelContact removed a•••@clalit.org.il · •••1033Contact removed (no phone or email listed)
    • The Chaim Sheba Medical Center at Tel HaShomer · Ramat Gan, IsraelContact removed h•••@sheba.health.gov.il · •••5432Contact removed (no phone or email listed)
    • Tel Aviv Sourasky Medical Center · Tel Aviv, IsraelContact removed y•••@tlvmc.gov.il · •••2575Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04414475
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Jul 1, 2020
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Karyopharm Medical Information
Contact
clinicaltrials@karyopharm.com
(888) 209-9326

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selinexor · Dexamethasone

Start the discussion